Legal Statement

GALDERMA LABORATORIES, L.P. IMPORTANT LEGAL INFORMATION
Copyright 2013 Galderma Laboratories, L.P.
P.O. Box 331329
Fort Worth, Texas 76163-1329.

All use of the METROGEL® (metronidazole) Gel, 1% Web site is subject to the terms and conditions set forth below. Any use of such Web pages constitutes the user's agreement to abide by the following terms and conditions.

Galderma METROGEL 1% Web pages are designed for educational purposes only. This information is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified health care provider. Galderma Laboratories, L.P. does not endorse or attest to the validity or accuracy of any treatments, medications, or non-Galderma products discussed herein. Before acting on any information contained on the Web pages, you agree that you will consult your health care provider to determine whether the information you are relying on is appropriate for your medical conditions.

All information provided by Galderma is owned by or licensed to Galderma. Galderma and its licensors retain all proprietary rights to the information contained on the pages. Except for making one hard copy print of the information or downloading the material for a one-time use, information on the pages may not be reproduced, transmitted, distributed, or displayed, without the express consent of Galderma. THIS WEB SITE IS PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. THIS WEB SITE COULD INCLUDE TECHNICAL INACCURACIES OR TYPOGRAPHICAL ERRORS. CHANGES ARE PERIODICALLY ADDED TO THE INFORMATION HEREIN; THESE CHANGES WILL BE INCORPORATED IN NEW EDITIONS OF THE WEB SITE. GALDERMA MAY MAKE IMPROVEMENTS AND/OR CHANGES IN THE PRODUCT(S) AND/OR THE PROGRAM(S) DESCRIBED IN THIS WEB SITE AT ANY TIME.

For further intellectual property information regarding the METROGEL 1% Web site, please contact
webmaster@galderma.com
© 2013 GALDERMA LABORATORIES, L.P. United States

IMPORTANT SAFETY INFORMATION

Indication: METROGEL® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with METROGEL 1% were nasopharyngitis, upper respiratory tract infection, and headache. Other adverse experiences reported when using topical metronidazole include skin irritation, transient redness, metallic taste, tingling or numbness of the extremities and nausea. Warnings/Precautions: METROGEL 1% should not be used by patients who are allergic to metronidazole or any ingredient in METROGEL 1%. Avoid contact of METROGEL 1% with the eyes as it may cause tearing. METROGEL 1% should be used with caution in patients with evidence of, or a history of, blood dyscrasia, and with patients taking blood thinning agents as they may experience prolonged prothrombin times. METROGEL 1% treatment should be discontinued if numbness or paresthesia of any extremity should occur.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.